Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)
Latest Information Update: 20 Sep 2022
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ocular inflammation; Postoperative pain
- Focus Therapeutic Use
- Sponsors EyeGate Pharma; Kiora Pharmaceuticals
- 17 May 2018 Status changed from active, no longer recruiting to completed.
- 05 Feb 2018 Primary endpoint has not been met. (Pain score = 0), according to an EyeGate Pharma media release.
- 05 Feb 2018 Primary endpoint has not been met. (AC cell count = 0), according to an EyeGate Pharma media release.